Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
232.37 MXN
−5.98 B MXN
455.59 M MXN
55.14 M
About Agios Pharmaceuticals, Inc.
Sector
CEO
Brian M. Goff
Headquarters
Cambridge
Website
Founded
2007
FIGI
BBG00PG377Y0
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
AGIO w24 2021. Waiting for clear uptrend.Weekly
Company not so old.
Consolidation of price
Daily
If price holds level of 57 could be buy, but i suppose profit depends on how fast they will do resarch of anticancer in 2022-2024 years.
Long on AGIOIsland type Reversal pattern on Abnormal Volume
New 30bar Highs on 2period ROC
Climactic action and supple demand imbalance
Longer term Wolf wave pattern on Weeklys and Daily’s
$AGIO Agios shares jump- sells Cancer Portfolio for $1.8bil
Could be a runner today on the news that is has agreed to sell its cancer portfolio .
"Servier will pay $1.8 billion in cash upfront and $200 million in potential future milestone payments for vorasidenib as well as a small percentage of royalties for U.S. net sales of acute myeloid leukemia tre
Agios Pharmaceuticals, Inc. Spikes pre market Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generatio
$AGIO Agios Pharma Bullish Trade above the 200MA
Alert set for break above the 200MA.
A cross above mid channel would be very bullish setting up a
move to the top of channel.
RSi very strong bounce of Mid-point
Volume beginning to increase
Short term target $46- $48
Agios Announces FDA Orphan Drug Designation Granted to MitapivatAGIO: Agios Pharmaceuticals, Inc.
2020-11-12 16:30:16
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
AGIO 8H: BEST Level to BUY/HOLD 90% gains(SL/TP)(STOCKS)Why get subbed to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AGIO is 1,085.00 MXN — it has increased by 86.36% in the past 24 hours. Watch AGIOS PHARMACEUTICALS, INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange AGIOS PHARMACEUTICALS, INC stocks are traded under the ticker AGIO.
AGIO stock has fallen by −4.89% compared to the previous week, the month change is a 84.92% rise, over the last year AGIOS PHARMACEUTICALS, INC has showed a 84.92% increase.
We've gathered analysts' opinions on AGIOS PHARMACEUTICALS, INC future price: according to them, AGIO price has a max estimate of 1,514.85 MXN and a min estimate of 929.11 MXN. Watch AGIO chart and read a more detailed AGIOS PHARMACEUTICALS, INC stock forecast: see what analysts think of AGIOS PHARMACEUTICALS, INC and suggest that you do with its stocks.
AGIO stock is 51.48% volatile and has beta coefficient of 2.45. Track AGIOS PHARMACEUTICALS, INC stock price on the chart and check out the list of the most volatile stocks — is AGIOS PHARMACEUTICALS, INC there?
Today AGIOS PHARMACEUTICALS, INC has the market capitalization of 41.07 B, it has increased by 4.07% over the last week.
Yes, you can track AGIOS PHARMACEUTICALS, INC financials in yearly and quarterly reports right on TradingView.
AGIOS PHARMACEUTICALS, INC is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
AGIO earnings for the last quarter are 319.59 MXN per share, whereas the estimation was 299.81 MXN resulting in a 6.60% surprise. The estimated earnings for the next quarter are −34.32 MXN per share. See more details about AGIOS PHARMACEUTICALS, INC earnings.
AGIOS PHARMACEUTICALS, INC revenue for the last quarter amounts to 177.33 M MXN, despite the estimated figure of 185.96 M MXN. In the next quarter, revenue is expected to reach 189.75 M MXN.
AGIO net income for the last quarter is 18.68 B MXN, while the quarter before that showed −1.76 B MXN of net income which accounts for 1.16 K% change. Track more AGIOS PHARMACEUTICALS, INC financial stats to get the full picture.
No, AGIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 383.00 employees. See our rating of the largest employees — is AGIOS PHARMACEUTICALS, INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AGIOS PHARMACEUTICALS, INC EBITDA is −7.91 B MXN, and current EBITDA margin is −1.43 K%. See more stats in AGIOS PHARMACEUTICALS, INC financial statements.
Like other stocks, AGIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AGIOS PHARMACEUTICALS, INC stock right from TradingView charts — choose your broker and connect to your account.